Anxiety & Stress Disorders

What is new in research on stress and anxiety disorders?

According to the chief medical officer of MindMed, it is time to look past the history of LSD.

Here are highlights from the fourth day of this year’s APA Annual Meeting.

Generalized anxiety disorder: has it been sidelined by MDD? MM-120 is a new treatment under investigation for this disorder, making waves.

What are the connections between what we eat and disorders such as anxiety and depression?

While benzodiazepine prescribing certainly carries risks, those risks have been demonstrably exaggerated in the minds of government officials, critics, and the public at large.

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.

What is new in research on cannabis?

The US Food and Drug Administration has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder.

Neuropsychiatric disorders regularly occur following traumatic brain injury and are often diagnosed within the first year postinjury. Diagnosis and treatment of neuropsychiatric disorders can be difficult due to a number of interacting factors, such as preinjury psychiatric history, lesion location, injury severity, substance misuse, and psychosocial complications. Clinicians should use a highly individualized approach to diagnosis and treatment planning.

These partnerships aim to address the mental health needs of underserved populations, including individuals with clinical depression, anxiety, and mood disorders.

New research finds whole-family collaborative care digital mental health interventions help manage disordered eating behaviors in adolescents aged 13-17.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

The FDA granted clearance for a transcranial magnetic stimulation technology indicated for major depressive disorder and obsessive-compulsive disorder.

What is new in research on COVID-19 and mental health?

Here are some updates from the world of psychiatry throughout the month of December.

Review the uses and forms of transcranial magnetic stimulation.

From a new look at the famous STAR*D study to updates from the National Academy of Sciences Conference on Adult ADHD, here are highlights from the week in Psychiatric Times.

“This is the first study to assess the standalone drug effects of MM-120 in the absence of any psychotherapeutic intervention.”

Addressing shame in the treatment of OCD is a crucial component of the therapeutic process. Here’s what you need to know.

From dopamine detoxification for problem gaming to connections between bacteria and anxiety and depression, here are highlights from the week in Psychiatric Times.

The results suggest that the bacterium Lactobacillus may aid in the management of stress and in the prevention of these disorders.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

What is new in research on anxiety symptoms and disorders?

Ketamine for anxiety? Researchers performed a systematic review and meta-analysis of ketamine’s anxiolytic effects.

Children have real worries driven by real threats when it comes to climate change.

"During the past 5 years has gabapentin retained its position as one of the top 10 drugs prescribed in the United States."

One reader believes psychiatrists and mental health clinicians should approach climate change with skepticism.